Completed PHASE2 INTERVENTIONAL 3-arm NCT00429091

A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study of the Safety and Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Sponsor: Abbott

Conditions ADHD Attention-Deficit/Hyperactivity Disorder

Interventions ABT-894 atomoxetine placebo

Updated 6 times since 2017 Last updated: Nov 1, 2010 Started: Jan 31, 2007 Primary completion: Aug 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on ADHD and Attention-Deficit/Hyperactivity Disorder, this trial is completed. The trial is conducted by Abbott and has accumulated 6 data snapshots since 2007. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jan 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abbott

Data source: Abbott

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Austin, United States , Bellaire, United States , Bellevue, United States , Boston, United States , Burlington, United States , Charleston, United States , Charlotte, United States , Clementon, United States , Eugene, United States , Libertyville, United States and 12 more locations